As of October 27, 2026, Inhibikase Therapeutics, Inc. is a publicly traded company (Nasdaq: IKT); its largest reported holder is RA Capital, with 9.9% on Schedule 13G/A of July 31, 2026, then Commodore Capital (9.9%). The largest insider holding is Frank M. Sands, a 10% owner, with 13,018,965 shares (9.3% of shares outstanding), per Form 4 of November 24, 2025 (Schedule 13G/A, July 31, 2026).
About to sign with, pay or invest in Inhibikase Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Inhibikase Therapeutics, Inc. a real, registered company?
- Inhibikase Therapeutics, Inc. files with the SEC under CIK 1750149 (its SEC filings).
- Its shares are listed under the ticker IKT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Wilmington, Delaware, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Inhibikase Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-10-27).
- Leadership changes: the latest reported is Dennis Berman, Director (Form 8-K filed 2026-10-20). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Perceptive Advisors (filed 2026-08-14).
Who are Inhibikase Therapeutics, Inc.'s owners and officers?
Inhibikase Therapeutics, Inc.: incorporated in Delaware; business address in Wilmington, Delaware; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-10-20).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-06-04)
- : Executive Officer (Form D, 2024-06-04)
- : Director (Form D, 2024-06-04)
- : Director (Form D, 2024-06-04)
- : Director (Form D, 2024-06-04)
- : Director (Form D, 2024-06-04)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Perceptive Advisors LLC | 6.9% |
| Schedule 13G/A, 2026-08-14 | Nantahala Capital Management, LLC | 4.3% |
| Schedule 13G/A, 2026-08-13 | Sands Capital Life Sciences Pulse Fund Ii, L.P. | 9.3% |
| Schedule 13G/A, 2026-07-31 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G, 2026-07-28 | Blackrock, Inc. | 5.9% |
| Schedule 13G, 2026-07-17 | Ra Capital Management, L.P. | 15.9% |
| Schedule 13G/A, 2026-05-15 | Commodore Capital LP | 9.9% |
| Schedule 13G/A, 2026-05-15 | Adar1 Capital Management, LLC | 9.9% |
| Schedule 13G/A, 2026-05-15 | Perceptive Advisors LLC | 8.9% |
| Schedule 13G/A, 2026-05-15 | Trails Edge Capital Partners, LP | 6.1% |
| Schedule 13G/A, 2026-02-17 | Perceptive Advisors LLC | 9.99% |
| Schedule 13G/A, 2026-02-17 | Fairmount Funds Management LLC | 9.9% |
Want the whole picture on Inhibikase Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Inhibikase Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Inhibikase Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-20 | Dennis Berman | Director | departed | 2026-10-19 |
Which insiders own Inhibikase Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 13,018,965 shares (9.3% of shares outstanding), on a joint filing (Form 4, 2025-11-24).
- Sands Capital Life Sciences Pulse Fund II, L.P., a 10% owner: 13,018,965 shares (9.3% of shares outstanding), on a joint filing (Form 4, 2025-11-24).
- Sands Capital Alternatives, LLC, a 10% owner: 13,018,965 shares (9.3% of shares outstanding), on a joint filing (Form 4, 2025-11-24).
- RA Capital Healthcare Fund LP, a 10% owner: 6,970,000 shares (5.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-07-31).
- RA Capital, a 10% owner: 6,970,000 shares (5.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-07-31).
Shares outstanding: 139,535,900 as of 2026-08-04, from the company's latest SEC cover page.
How much has Inhibikase Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-06-04 | $0 | $8M |
| Form D, 2023-02-07 | $4.20M | $4.20M |
Keep reading
More on Inhibikase Therapeutics, Inc. and the records around it.
Inhibikase Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Sands Capital Life Sciences Pulse Fund II, L.P. also filed stake reports on 3 other companies: Acrivon Therapeutics, Inc. (Aug 2026), Alamar Biosciences, Inc. (Jul 2026), Beta Bionics, Inc. (Aug 2025)
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
- Trails Edge Capital Partners, LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), Faeth Therapeutics, Inc. (Aug 2026), Neurogene Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/inhibikase-therapeutics